Login to Your Account



Search

Search results

Pharma: Clinic roundup

Bayer Healthcare , of Whippany, N.J., reported positive results from the PROTECT VIII trial evaluating the company’s investigational long-acting site-specific pegylated recombinant human factor VIII compound BAY 94-9027. (BioWorld-Today-2014 ...

BioWorld Today - Staff - 2014-02-19 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Cempra Inc. , of Chapel Hill, N.C., presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin vs. levofloxacin i ...

BioWorld Today - Staff - 2013-05-21 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• LEO Pharma UK , of Princes Risborough, UK, reported that data published in the Journal of the American Medical Association Dermatology demonstrated the long-term effectiveness of Picato (ingenol mebutate) in treating actinic keratosis (AK ...

BioWorld Today - Staff - 2013-03-22 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, reported top-line results from the GEMINI I Phase III study of vedolizumab in 895 patients with moderately to severely active ulcerative colitis who have failed at least one conventional thera ...

BioWorld Today - Staff - 2012-02-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• The ALS Therapy Development Institute (ALS TDI) said it plans to launch a Phase II trial of TDI 132 (fingolimod/Gilenya) in amyotrophic lateral sclerosis. Gilenya, a first-in-class sphingosine-1-phosphate (S1P) receptor modulator marketed by ...

BioWorld Today - Staff - 2012-02-15 01:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Ipsen SA , of Paris, reported results of the international phase III clinical trial of Dysport Next Generation (DNG), an injectable form of botulinum toxin type A, in cervical dystonia. DNG was clinically and statistically superior to placebo in th ...

BioWorld Today - Staff - 2014-02-06 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Eli Lilly and Co. , of Indianapolis, reported data from a Phase III study showing that both Cialis (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score, compared to placebo, in men with signs an ...

BioWorld Today - Staff - 2012-02-08 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, said the randomized Phase II (PALOMA-1) of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for the combination of pal ...

BioWorld Today - Staff - 2014-02-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line data from two Phase III studies of irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small-cell lung cancer (NSCLC), neither of which met their primary objectives. ...

BioWorld Today - Staff - 2014-01-28 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line results from a Phase III study of ALO-02 (oxycodone hydrochloride/naltrexone hydrochloride extended-release capsules) in patients with moderate to severe chronic low back pain, showing that the drug met th ...

BioWorld Today - Staff - 2014-01-24 01:00 - 0 comments - 0 attachments